Skip to main content
SpringerLink
Log in

Alendronic acid: effective therapy for postmenopausal osteoporosis

  • New Drugs and Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jeal W, Barradell LB, McTavish D. Alendronate: a review of its pharmacological properties and therapeutic efficacy in postmenopausal osteoporosis. Drugs 1997; 53(3): 415–434

    Article  PubMed  CAS  Google Scholar 

  2. Compston JE. Prevention and management of osteoporosis: current trends and future prospects. Drugs 1997; 53(5): 727–735

    Article  PubMed  CAS  Google Scholar 

  3. Patel S, Lyons AR, Hosking DJ. Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use. Drugs 1993 Oct; 46: 594–617

    Article  PubMed  CAS  Google Scholar 

  4. Dunn CJ, Fitton A, Sorkin EM. Etidronic acid: a review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs Aging 1994 Dec; 5(6): 446–74

    Article  PubMed  CAS  Google Scholar 

  5. Plosker GL, McTavish D. Intranasal salcatonin (salmon calcitonin): a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 1996; 8(5): 378–400

    Article  PubMed  CAS  Google Scholar 

  6. British National Formulary No. 33. London: The Pharmaceutical Press, 1997 Mar

  7. 1997 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1997

  8. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995 Nov 30; 333(33): 1437–43

    Article  PubMed  CAS  Google Scholar 

  9. Devogelaer JP, Broll H, Correa-Rotter R, et al. Oral alendronate induces progressive increases in bone mass of the spine, hip and total body over three years in postmenopausal women with osteoporosis. Bone 1996 Feb; 18(2): 141–50

    Article  PubMed  CAS  Google Scholar 

  10. Tucci JR, Tonino RP, Emkey RD, et al. Effect of three-years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 1996; 101: 488–501

    Article  PubMed  CAS  Google Scholar 

  11. Adami S, Passeri M, Ortolani S, et al. Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995; 17: 383–90

    Article  PubMed  CAS  Google Scholar 

  12. Sandoz Pharmaceuticals Corporation. Miacalcin (calcitonin-salmon) Nasal spray prescribing information. East Hanover, New Jersey 07936; 1995.

  13. Passeri M, Baroni MC, Pedrazzoni M, et al. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner 1991 Dec; 15: 237–47

    Article  PubMed  CAS  Google Scholar 

  14. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996 Dec 7; 348: 1535–41

    Article  PubMed  CAS  Google Scholar 

  15. Merck & Co. Alendronate prescribing information. West Point, Pennsylvania, USA, Sept 1995.

    Google Scholar 

  16. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993; 94: 646–650

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Alendronic acid: effective therapy for postmenopausal osteoporosis. Drugs Ther. Perspect 10, 1–5 (1997). https://doi.org/10.2165/00042310-199710010-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199710010-00001

Keywords

Search

Navigation